The COVID-19 pandemic has brought the world literally to a standstill. Council of Scientific and Industrial Research (CSIR), India through its 38 laboratories and expertise in diverse areas ranging from aerospace to buildings to genomics to chemicals, quickly sprang into action developing COVID-19 interventions. CSIR, India's rich R&D knowledgebase is embodied in the rapid testing, cost-effective diagnostic kits, virus culture, genome sequencing and disease surveillance. With the perfect blend of scientific knowledge, technical expertise, industry linkages and governmental interfaces, through innovations and improvisations CSIR, India has come up with many technologies and products to be deployed against COVID-19. To combat the virus, CSIR, India is exploring all avenues and supporting new ideas that have a clear deployment strategy and has setup focused groups to look at multiple pathways for developing drugs: i) Molecular modelling of drugs; ii) Host-target interactions; iii) Crystal  engineering; iv) Batch to continuous process; v) In-silico screening of existing drugs and natural products; vi) Scouting for non-infringing routes, and vii) Host-dependent pathways for APIs.  One of the many drugs technology developed by CSIR is the “Cost Effective Process Technology of Favipiravir”. It is Repurposed generic drug. The cost effective process of API with locally available chemicals is developed by CSIR, India. CIPLA, India has already been provided with API and key starting materials for this technology.